EBITDA for Q4 FY22 is at 1300 crore. The EBITDA margin stood 23.9% in Q4 March 2021 higher than 23.8% in Q4 December 2021 and 23.8% in Q3 December 2021.
Selling, General & Administrative (SG&A) expenses increased 9% YoY and rose 2% QoQ to Rs 1567.40 crore.
Research and Development (R&D) expenses rose 6% YoY and rose 4% QoQ to to Rs 432.60 crore.
During the quarter, revenues from Emerging Markets segment stood at Rs 1201.3 crore. Year-on-year growth of 36% and sequential growth of 4%.
Revenues from India market stood at Rs 968.9 crore. Year-on-year growth of 15% and sequential decline of 6%.
Revenues from Europe market stood at Rs 444.4 crore. Year-on-year growth of 12% and sequential growth of 10%.
Revenues from North America market stood at Rs 2000 crore. Year-on-year growth of 14% and sequential increase of 7%.
Revenues from Global Generics (GG) stood at Rs 4611.80 crore. Year-on-year growth of 19% and sequential growth of 4%. The YoY & QoQ growth was driven by growth across all markets, however the QoQ growth was partially impacted due to a decline in revenues in India.
Revenues from Pharmaceutical Services and Active Ingredients (PSAI) segment for Q4 stood at Rs 755.7 crore, YoY decline of 5% and QoQ growth of 4%. YoY decline was primarilydue to lower volumes and price erosion while the QoQ growth was driven by new product sales.
The board recommended a final dividend of Rs 30 per equity share for the financial year 2021-22.
Commenting on the results, Co-Chairman & MD, G V Prasad said: “We delivered healthy growth in revenue, though the profits were impacted by impairment charges. In spite of multiple external challenges, our core businesses performed well driven by an increase in market share, some strong launches and productivity improvement. We will continue to focus on growing our core businesses, invest in future growth drivers, and work towards greater integration of Sustainability in our businesses.
Dr. Reddy's Laboratories is an integrated pharmaceutical company. It offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Shares of Dr. Reddy's Laboratories were up 0.71% at Rs 3935.70 on the BSE.
Powered by Capital Market - Live News